A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Status:
Not yet recruiting
Trial end date:
2025-01-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of
nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with
untreated advanced/metastatic hepatocellular carcinoma (HCC).